Madrigal Pharmaceuticals (MDGL) Equity Ratio (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Equity Ratio data on file, last reported at 0.44 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.44, down 37.9% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.44 (down 37.9% YoY), and the FY2025 annual result was 0.48, down 33.89% from the prior year.
• Equity Ratio slipped to 0.44 in Q1 2026 per MDGL's latest filing, from 0.48 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.79 in Q1 2024 and troughed at 0.07 in Q3 2022.
• A 5-year average of 0.53 and a median of 0.54 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio tumbled 91.28% in 2022, then surged 674.46% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.54 in 2022, then rose by 16.23% to 0.63 in 2023, then advanced by 14.38% to 0.72 in 2024, then plunged by 33.89% to 0.48 in 2025, then fell by 7.46% to 0.44 in 2026.
• Business Quant data shows MDGL's Equity Ratio at 0.44 in Q1 2026, 0.48 in Q4 2025, and 0.46 in Q3 2025.